|
RESOURCES
Search the Clearinghouse
About AVAC
Join the AVAC mailing list
Submissions to the Clearinghouse
Links
Glossary
AIDS Vaccine Handbook(2005)
Contact Us
Disclaimer
PRIMARY CONTENT
General & Introductory Information - A basic introduction for readers who are new to AIDS vaccine research. Why do we need an AIDS vaccine? How will an AIDS vaccine work? These and other basic questions are addressed, with suggestions for further reading.
Vaccine Science, Research & Development - An overview of science and research issues, including the major scientific challenges and concepts, as well as current approaches to AIDS vaccine design.
Clinical Trials Around the World - There are now more candidate AIDS vaccines in or near human clinical trials than ever before. This section offers an introductory guide to the issues, the trials, and the products.
Communities and Cohorts - To determine if an experimental AIDS vaccine is safe and effective, it has to be tested in the populations that will use it - populations at high risk for HIV infection. This section introduces several of these communities, the challenges involved in including them in trials and why it's a priority that we do so.
Participation in a Trial - Without healthy, HIV-negative individuals who are willing to volunteer for clinical trials, the development of an AIDS vaccine would be impossible. This section describes the process of participating in a trial and answers the common questions of potential volunteers.
Ethics & Human Rights - Ethics and human rights concerns infuse every aspect of AIDS vaccine research and testing. This section provides an introduction to the major issues involved.
Community Involvement - Community involvement has always been critical in the fight against AIDS. This section outlines some of the ways people can involve their communities in AIDS vaccine issues, advocacy and trials.
Vaccine Advocacy - Advocacy has played an incredible role in the fight against HIV/AIDS and it is imperative that people continue to advocate for the development and delivery of safe and effective AIDS vaccines. This section describes some of the key advocacy issues in AIDS vaccine research.
Policy - The speed and equity with which an AIDS vaccine reaches the world will be determined to a large degree by the actions of governments and international organizations. This section provides an introductory discussion of some of the public policy issues that can affect AIDS vaccine research, development, testing, and delivery.
Global Access - Action is needed now to prepare for worldwide distribution of AIDS vaccines in the years to come. This section discusses issues related to ensuring global access to AIDS vaccines once they become available.
Comprehensive Response to AIDS - AIDS vaccine research is only one element of what must be a comprehensive response to the pandemic. This section discusses shared advocacy issues among AIDS treatment, prevention, and research advocates.
Global HIV Vaccine Enterprise - The Global HIV Vaccine Enterprise is an alliance of independent partners from the major scientific, funding and policy organizations involved in AIDS vaccine research and development. This section introduces the Global HIV Vaccine Enterprise, its members, its mission and its priorities for the months and years ahead.
Advocates' Network - Advocacy efforts worldwide are vital to advancing the development and delivery of safe and effective AIDS vaccines. This network provides members with regular email announcements, updates and notices of events or activities related to AIDS vaccine research around the world. In addition to regular updates, advocates can submit events and activities to be included in the Advocates' Network Calendar - a calendar of AIDS vaccine related activities around the world
PrEP Watch - PrEP Watch is a comprehensive information source on pre-exposure prophylaxis prevention research. PrEP Watch features a regularly-updated table of planned and ongoing trials as well as the current information including scientific findings, advocacy documents, and meeting reports.
|
|
|
